BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 16447800)

  • 1. [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].
    Miyawaki S; Emi N; Mitani K; Oyashiki K; Kitamura K; Morishita T; Ogawa H; Komatsu N; Soma T; Tamaki T; Kosugi H; Ohnishi K; Mizoguchi H; Hiraoka A; Kodera Y; Ueda R; Morishima Y; Nakagawa M; Tobita T; Sugimoto K; Chiba S; Inoue N; Hamaguchi M; Koga D; Tamaki H; Naoe T; Sugiyama H; Takaku F
    Rinsho Ketsueki; 2005 Dec; 46(12):1279-87. PubMed ID: 16447800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance of monitoring WT1 mRNA levels of peripheral blood and bone marrow in acute myeloid leukemia].
    Kitamura K; Nakano Y; Watamoto K; Koga D; Naoe T
    Rinsho Ketsueki; 2010 Dec; 51(12):1748-55. PubMed ID: 21258184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
    Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
    Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
    Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
    Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
    Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follow-up of minimal residual disease in acute childhood lymphoblastic leukemia by WT1 gene expression in the peripheral blood: the Hungarian experience.
    Magyarosy E; Varga N; Timár J; Rásó E
    Pediatr Hematol Oncol; 2003; 20(1):65-74. PubMed ID: 12687755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants.
    Siehl JM; Reinwald M; Heufelder K; Menssen HD; Keilholz U; Thiel E
    Ann Hematol; 2004 Dec; 83(12):745-50. PubMed ID: 15340762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
    Østergaard M; Olesen LH; Hasle H; Kjeldsen E; Hokland P
    Br J Haematol; 2004 Jun; 125(5):590-600. PubMed ID: 15147374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
    Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
    Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
    Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia.
    Huh HJ; Huh JW; Yoo ES; Seong CM; Lee M; Hong KS; Chung WS
    Am J Hematol; 2005 Aug; 79(4):267-73. PubMed ID: 16044449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
    J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
    Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
    Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia.
    Osborne D; Frost L; Tobal K; Liu Yin JA
    Bone Marrow Transplant; 2005 Jul; 36(1):67-70. PubMed ID: 15908982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative real-time RT-PCR detects elevated Wilms tumor gene (WT1) expression in autologous blood stem cell preparations (PBSCs) from acute myeloid leukemia (AML) patients indicating contamination with leukemic blasts.
    Siehl JM; Thiel E; Leben R; Reinwald M; Knauf W; Menssen HD
    Bone Marrow Transplant; 2002 Mar; 29(5):379-81. PubMed ID: 11919726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease.
    Polak J; Hajkova H; Haskovec C; Cechova H; Marinov I; Mikulenkova D; Markova J; Markova M; Vitek A; Valkova V
    Neoplasma; 2013; 60(1):74-82. PubMed ID: 23067220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.